SPE2D2-25-D-0003 - Methylphenidate HCL ER Tablets Contract

Contract SPE2D2-25-D-0003 is an award issued by DLA Troop Support to SpecGx LLC for the procurement of Methylphenidate HCL ER 10MG and 20MG tablets. The contract consists of a base year and four option years, with a total estimated value of 4,154,058.30 dollars. The base period value is 830,811.66 dollars, with fixed annual quantities of 7,091 bottles of 10MG tablets at 47.91 dollars per unit and 9,951 bottles of 20MG tablets at 49.35 dollars per unit. Manufacturing is conducted at the SpecGx LLC plant in Hobart, NY, with delivery designated as FOB Destination to DLA and VA Pharmaceutical Prime Vendors. Modification P00004 exercises the first option year for the period of December 10, 2025, through December 9, 2026, pursuant to FAR 52.217-9. Previous modification P00002 integrated critical federal clauses, including those related to the Federal Acquisition Supply Chain Security Act. The contractor, identified as a small business under NAICS 325412, must adhere to strict supply chain security reporting, cybersecurity measures per DFARS 252.204-7012, and electronic payment requirements via the System for Award Management. Products must be labeled with the National Drug Code and Item Unique Identification in accordance with DFARS 252.211-7003.